vs
Side-by-side financial comparison of Lantheus Holdings, Inc. (LNTH) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $406.8M | — | ||
| Q3 25 | $384.0M | — | ||
| Q2 25 | $378.0M | — | ||
| Q1 25 | $372.8M | — | ||
| Q4 24 | $391.1M | — | ||
| Q3 24 | $378.7M | — | ||
| Q2 24 | $394.1M | — | ||
| Q1 24 | $370.0M | — |
| Q4 25 | $54.1M | — | ||
| Q3 25 | $27.8M | — | ||
| Q2 25 | $78.8M | — | ||
| Q1 25 | $72.9M | — | ||
| Q4 24 | $-11.8M | — | ||
| Q3 24 | $131.1M | — | ||
| Q2 24 | $62.1M | — | ||
| Q1 24 | $131.1M | — |
| Q4 25 | 59.2% | — | ||
| Q3 25 | 57.9% | — | ||
| Q2 25 | 63.8% | — | ||
| Q1 25 | 63.8% | — | ||
| Q4 24 | 63.5% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 64.9% | — | ||
| Q1 24 | 65.4% | — |
| Q4 25 | 19.0% | — | ||
| Q3 25 | 11.4% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 27.4% | — | ||
| Q4 24 | 29.1% | — | ||
| Q3 24 | 35.3% | — | ||
| Q2 24 | 26.1% | — | ||
| Q1 24 | 28.8% | — |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 19.6% | — | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | 15.8% | — | ||
| Q1 24 | 35.4% | — |
| Q4 25 | $0.86 | — | ||
| Q3 25 | $0.41 | — | ||
| Q2 25 | $1.12 | — | ||
| Q1 25 | $1.02 | — | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $1.79 | — | ||
| Q2 24 | $0.88 | — | ||
| Q1 24 | $1.87 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
